June 24, 2026 01:56 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
No Hindi, no NEET: Vijay reignites Tamil Nadu's biggest political flashpoints | Messi creates World Cup history with record-breaking double; Mbappe equals Klose's mark hours later | Tech giant Oracle slashes 21,000 jobs while betting big on AI | 'Italy and I never beg': Meloni fires back at Trump over G7 photo claim | No more 'brother': Stalin's formal birthday greeting to Rahul reflects deepening rift | TMC seeks disqualification of 20 rebel MPs, Abhishek says 'membership should go' | Nara Lokesh pitches Andhra Pradesh as investment hub during Kolkata visit, sets $2.4 trillion economy goal | 'Least restrictive option': Setback for Telegram as Delhi HC backs Centre's ban ahead of NEET-UG re-test | Fortuner torched, BJP leaders burnt alive: Sand mining feud ends in triple murder in Chhattisgarh | 'If Modi is the leader and India is attacked, we'll be there': Trump's strong assurance at G7

Strides Arcolab signs agreement with Gilead Sciences

| | Jan 21, 2015, at 02:38 am
Bangalore/Kolkata, Jan 20 (IBNS): Strides Arcolab Limited (Strides) on Tuesday announced that it has entered into a licensing agreement with Gilead Sciences, Inc. under which Gilead has extended non-exclusive rights to Strides to manufacture and distribute Tenofovir Alafenamide (TAF), both as a single agent product and in combination with other drugs.
The license being granted to Strides extends to 112 countries, which together account for more than 30 million people living with HIV.
 
As part of the licensing agreement, pending U.S. Food and Drug Administration (US FDA) approval of the Gilead product, Strides will receive a technology transfer from Gilead, enabling Strides to manufacture low-cost versions of TAF for developing countries.
 
TAF is a novel nucleotide reverse transcriptase inhibitor that has demonstrated high antiviral efficacy at a dose 10 times lower than Gilead’s Viread (tenofovir disoproxil fumarate), as well as an improved renal and bone safety profile.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Related Videos
RBI announces repo rate cut Jun 06, 2025, at 10:51 am
FM Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:45 pm
Nirmala Sitharaman on Budget 2024 Jul 23, 2024, at 09:30 pm